Evidence map›Paper›PMID 29732165›Full record

ArticleNanoscale horizons2016

Porous silicon-graphene oxide core-shell nanoparticles for targeted delivery of siRNA to the injured brain.

Jinmyoung Joo, Ester J Kwon, Jinyoung Kang, Matthew Skalak, Emily J Anglin, Aman P Mann, Erkki Ruoslahti, Sangeeta N Bhatia, Michael J Sailor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale horizons, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Nucleic acid drug vectors for diagnosis and treatment of brain diseases.Signal transduction and targeted therapy · 2023
    Review
  7. Article
  8. Article
  9. Graphene Oxide Thin Films with Drug Delivery Function.Nanomaterials (Basel, Switzerland) · 2022
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jinmyoung JooDepartment of Chemistry, University of California, San Diego, La Jolla, CA 92093, USA.
Ester J KwonHarvard-MIT Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Jinyoung KangDepartment of Nanoengineering, University of California, San Diego, La Jolla, CA 92093, USA.
Matthew SkalakHarvard-MIT Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Emily J AnglinDepartment of Chemistry, University of California, San Diego, La Jolla, CA 92093, USA.
Aman P MannCancer Research Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Erkki RuoslahtiCancer Research Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Sangeeta N BhatiaHarvard-MIT Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Michael J SailorDepartment of Chemistry, University of California, San Diego, La Jolla, CA 92093, USA.

Funding

Peptide-mediated delivery of siRNA for treatment of ovarian cancerF32CA177094 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KWON, ESTER J. · 2013 to 2016
$138k
Howard Hughes Medical InstituteNCI NIH HHS F32 CA177094
6 · The paper itself

Abstract

We report the synthesis, characterization, and assessment of a nanoparticle-based RNAi delivery platform that protects siRNA payloads against nuclease-induced degradation and efficiently delivers them to target cells. The nanocarrier is based on biodegradable mesoporous silicon nanoparticles (pSiNPs), where the voids of the nanoparticles are loaded with siRNA and the nanoparticles are encapsulated with graphene oxide nanosheets (GO-pSiNPs). The graphene oxide encapsulant delays release of the oligonucleotide payloads

Identifiers

PMID29732165
PMCPMC5935492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.